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ABSTRACT
Vascular endothelial growth factor (VEGF), a key angiogenic and permeability factor, plays an important
role in new blood vessel formation. However, abnormal VEGF-induced VEGFR2 signaling leads to
hyperpermeability. We have shown previously that Rap1, best known for promoting cell adhesion and
vessel stability, is a critical regulator of VEGFR2-mediated angiogenic and shear-stress EC responses. To
determine the role of Rap1 role in endothelial barrier dynamics, we examined vascular permeability in EC-
specific Rap1A- and Rap1B-knockout mice, cell–cell junction remodeling and EC monolayer resistivity in
Rap1-deficient ECs under basal, inflammatory or elevated VEGF conditions. Deletion of either Rap1
isoform impaired de novo adherens junction (AJ) formation and recovery from LPS-induced barrier
disruption in vivo. However, only Rap1A deficiency increased permeability in ECs and lung vessels.
Interestingly, Rap1B deficiency attenuated VEGF-induced permeability in vivo and AJ remodeling in vitro.
Therefore, only Rap1A is required for the maintenance of normal vascular integrity. Importantly, Rap1B is
the primary isoform essential for normal VEGF-induced EC barrier dissolution. Deletion of either Rap1
isoform protected against hyper permeability in the STZ-induced diabetes model, suggesting clinical
implications for targeting Rap1 in pathologies with VEGF-induced hyperpermeability.
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INTRODUCTION
The endothelial cell layer lining blood vessels constitutes a barrier that restricts the movement of water,
proteins and blood cells between the intravascular and interstitial compartments. Exacerbated permeability
associated with pathological conditions such as inflammation or diabetes leads to vascular leakage, edema
and organ failure (Dejana et al., 2009; Nagy et al., 2008). While maintenance of the endothelial barrier (EB)
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is critical for end organ function (Rodrigues and Granger, 2015), dynamic regulation of the EB is required
for angiogenesis during development and for wound healing after birth. In particular, vascular endothelial
growth factor (VEGF), a major angiogenic factor first identified as a permeabilizing factor (Senger et al.,
1983), plays a key role in regulating physiological vascular permeability during vessel formation.
The EB is maintained by adherens junctions (AJs), tight junctions and their interactions with the underlying
actomyosin cytoskeleton. At the core of AJs are homophilic, trans interactions of transmembrane receptor
vascular endothelial (VE)-cadherin (Harris and Nelson, 2010). The cytoplasmic tail of VE-cadherin is
connected to the actin cytoskeleton via a number of proteins, including β-catenin, and is involved in
transmitting signals that affect both the VE-cadherin adhesive function and outside-in signaling, both of
which are crucial for vessel formation (Carmeliet et al., 1999). These functions of VE-cadherin are mediated
by several signaling partners (Dejana and Giampietro, 2012), including the small GTPase Rap1, which has
been shown to promote AJ assembly (Cullere et al., 2005; Glading et al., 2007; Kooistra et al., 2005;
Wittchen et al., 2005) and attenuate thrombin-induced junction dissolution (Birukova et al., 2008). In
isolated endothelial cells (ECs), active, GTP-bound Rap1 promotes the EB via direct enforcement of VE-
cadherin adhesion and junction integrity via Krit-1/CCM1 (Béraud-Dufour et al., 2007; Chrzanowska-
Wodnicka, 2013; Glading et al., 2007), and indirectly via dynamic regulation of the actomyosin
cytoskeleton and Rho-dependent tension (Ando et al., 2013; Chrzanowska-Wodnicka, 2017; Noda et al.,
2010; Post et al., 2013, 2015; Tawa et al., 2010; Wilson et al., 2013). AJ disassembly, in turn, is triggered by
signaling initiated by vascular permeability factors. Among them, VEGF plays a key role, as VEGF-induced
activation of VEGF receptor 2 (VEGFR2) on ECs triggers several signaling pathways that modulate VE-
cadherin adhesive properties, leading to junction dissolution. These pathways include activation of Src
family kinases (Eliceiri et al., 1999; Zachary and Gliki, 2001), and converge on phosphorylation and
internalization of VE-cadherin and its dissociation from the actin cytoskeleton (Gavard, 2009), altering
adhesive properties of VE-cadherin (Esser et al., 1998) and leading to AJ dissolution and increased
permeability (Carmeliet, 2003; Lin et al., 2003). Inhibition of VE-cadherin phosphorylation blocks
angiogenesis (Lin et al., 2003).
While most studies, particularly in vitro, define the role of Rap1 as a positive regulator of cell–cell adhesion,
in vivo studies suggest that Rap1 regulation of the EB is more complex. Two closely related isoforms of
Rap1: Rap1A and Rap1B, with identical effector domains and overall 95% homology but divergent C-
terminus involved in membrane attachment, are expressed in different proportions in most mammalian cells,
with Rap1A preferentially localized to cell–cell junctions in cultured ECs (Wittchen et al., 2011). While EC-
specific deletion of either isoform does not lead to obvious vascular defects (Chrzanowska-Wodnicka et al.,
2015), EC-specific double knockout of Rap1A and Rap1B isoforms (Rap1-ECKO) leads to lethality around
E13.5 (Chrzanowska-Wodnicka et al., 2015), with hemorrhage and engorgement of perineural vessels, and
bleeding as a likely cause of death, suggesting a redundant function of Rap1A and Rap1B in vascular barrier
formation. Interestingly, however, EC-specific deletion of both Rap1 isoforms after birth did not interfere
with normal cell–cell junction formation or lead to a gross vascular defect (Lakshmikanthan et al., 2015).
This suggests that Rap1 may have different functions at different stages of vessel formation and
maintenance. Furthermore, our recent findings implicate Rap1 as an important positive regulator of
VEGFR2 signaling. In response to VEGF, Rap1 promotes VEGFR2 activation in ECs via integrin α β
(Lakshmikanthan et al., 2011) and is required for VEGF-dependent angiogenesis (Carmona et al., 2009;
Chrzanowska-Wodnicka et al., 2008; Lakshmikanthan et al., 2011). More recently, we demonstrated that
Rap1 is required for shear stress-induced VEGFR2 transactivation, leading to nitric oxide (NO) release and
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endothelial homoeostasis (Lakshmikanthan et al., 2015). These findings suggested that Rap1 might also act
as a positive regulator of VEGF-induced permeability.
In this study, we took advantage of EC-specific Rap1A-knockout (Rap1A-ECKO) and EC-specific Rap1B-
knockout (Rap1B-ECKO) mice, to address, for the first time to our knowledge, the function of the two Rap1
isoforms in EB maintenance, de novo formation after barrier disruption, and in particular, VEGF-induced
remodeling. We examined the effect of Rap1A and Rap1B deficiency on AJs in vitro. Interestingly, we
found that the two isoforms play a similar, redundant function promoting de novo junction formation.
However, once the EB is established, there is an isoform-specific requirement for EB maintenance. Lastly,
because our study suggested a novel role of Rap1 in promoting VEGF-induced EB disassembly, we
examined the effect of endothelial Rap1 deletion on pathological hyper-permeability associated with early
diabetes. Our study suggests a novel role of two Rap1 isoforms in preventing pathological
hyperpermeability.
RESULTS
Endothelial Rap1A promotes vessel barrier maintenance in lungs in vivo
First, to determine the functional significance of each Rap1 isoform in EB maintenance in vivo, we
examined the effect of endothelial-specific deletion of Rap1A or Rap1B on basal permeability following
perfusion with Evan's Blue. The lung is often used as a model organ because of the prevalence of
continuous endothelium, in which cell–cell junctions are a primary determinant of permeability (Tse and
Stan, 2010). We found that while basal permeability was unaltered in lungs from Rap1B-ECKO mice, it was
slightly but significantly increased in lungs from Rap1A-ECKO mice (Fig. 1A). Interestingly, permeability
was also increased in lungs of mice missing all but one Rap1b allele, but not in mice missing all but one
Rap1a allele (Fig. S1), suggesting that heterozygous expression of Rap1A is sufficient to maintain a normal
endothelial barrier. Because Tie2-Cre is also active in BM-derived cells, we examined basal permeability in
the Rap1A-ECKO engrafted with WT bone marrow (WT–Rap1A-ECKO chimeras) in order to attribute the
phenotype to ECs. We found that basal vascular permeability in chimeric Rap1A-ECKO mice engrafted
with WT marrow was still elevated, indicating that Rap1a deficiency in the endothelium was responsible for
decreased barrier function (Fig. 1B). We observed a similar increase in lung permeability in endothelial-
restricted Rap1A (Rap1A )-knockout but not Rap1B (Rap1B )-knockout mice (Fig. 1C).
Interestingly, we did not detect increased vascular permeability in other organs examined (Fig. 1C). Because
Rap1B is the predominant Rap1 isoform in mouse endothelium (Lakshmikanthan et al., 2011) and Rap1A-
ECKO mice have a higher total Rap1 content than Rap1B-ECKO mice, this suggested that Rap1A
specifically is required for maintenance of basal permeability. These findings suggested that the elevated
basal permeability in Rap1A-ECKO mice is not due to a quantitative difference in total Rap1 content but is
rather due to the specific role of Rap1A in the maintenance of the EB in the continuous endothelium in
lungs.
Rap1A is required for maintenance of adherens junction organization in vitro
To gain insight into the role of Rap1A in EB maintenance, we utilized primary mouse lung endothelial cells
(MLECs) from Rap1-ECKO and WT mice to examine the effect of Rap1 isoform depletion on the
architecture of EC junctions (Fig. 2), as alteration of AJ architecture correlates with increased endothelial
permeability (Dejana et al., 2009). MLECs from Rap1-ECKO mice provide a good model of Rap1
deficiency, but also, being of mostly microvascular origin, provide a more physiologically relevant model of
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microvessel permeability than commonly studied human umbilical vein endothelial cells (HUVECs).
Because surface expression of VE-cadherin was unchanged in ECs from Rap1-deficient mice, compared
with expression in Cre-negative controls (Fig. S2), we examined the morphology of adherens junctions
(AJs) in MLECs from these mice. VE-cadherin and β-catenin immunofluorescence was examined in EC
monolayers by confocal microscopy. We found that in WT and Rap1B-deficient (ΔRap1B) ECs, the AJ
complex proteins VE-cadherin and β-catenin localized predominantly to the plasma membrane, where they
formed a continuous smooth line, consistent with the presence of mature AJs (Fig. 2). In contrast, in
Rap1A-deficient (ΔRap1A) EC monolayers, VE-cadherin and β-catenin formed fragmented, disorganized
AJs with short clusters perpendicular to the plasma membrane, typical of immature AJs (Fig. 2). To
quantify this effect, we plotted histograms of β-catenin fluorescence intensities along a line perpendicular to
the contacts, as previously described (Smutny et al., 2010). The shape of fitted histograms for both WT and
ΔRap1B ECs was very similar and formed a sharp, narrow fluorescence peak corresponding to a narrow
localized β-catenin distribution (Fig. 2). However, the fluorescence peak of the ΔRap1A EC histogram was
much wider, and area under the curve was larger, consistent with a wider, more disorganized β-catenin
distribution. Therefore, whereas Rap1B is redundant, Rap1A is required for maintenance of steady-state
endothelial AJ organization in vitro, a finding consistent with a preferred localization of Rap1A to the
plasma membrane (Wittchen et al., 2011).
Rap1A and Rap1B promote barrier re-formation following LPS-induced disruption
Next, to investigate the role of both Rap1 isoforms in the re-formation of EB function in vivo following its
disruption, we measured lung vascular permeability in the LPS-induced inflammation model, in which
increased endothelial permeability occurs as a result of loss of cell–cell contacts (Mehta and Malik, 2006).
We found that endothelial deletion of either Rap1A or Rap1B led to increased vascular permeability,
compared with Cre-negative controls (Fig. 3A). Perturbed barrier function, increased leakiness and edema
are major factors that contribute to organ damage in sepsis (Ait-Oufella et al., 2010; Ince et al., 2016). To
determine the functional consequences of increased vascular permeability on organ function, we examined
mouse survival in the LPS-induced sepsis model. We found that deletion of either isoform led to increased
lethality in LPS-induced sepsis (Fig. 3B). These findings suggest that deficiency of either Rap1A or Rap1B
leads to a decreased ability to reform an EB, with significant consequences on recovery following the
inflammatory insult.
Barrier re-formation in vitro
Increased vascular permeability followed by an increased death rate of Rap1-deficient mice in response to
LPS suggests that endothelial barrier re-formation following injury is impaired in Rap1-ECKO mice (Ait-
Oufella et al., 2010). Re-establishment of VE-cadherin homophilic binding is essential for barrier re-
formation after disruption (Vestweber et al., 2009). To determine whether defective VE-cadherin-based
junction formation in ECs underlies the increased permeability in ΔRap1 ECs, we examined the effect of
deleting each isoform on the kinetics of AJ re-formation in a ‘calcium switch’ method (Martinez-Palomo et
al., 1980). To this end, WT, ΔRap1A and ΔRap1B ECs were incubated in the presence of the calcium
chelator EDTA, which leads to the disruption of the Ca -dependent VE-cadherin junction. They were then
incubated with regular Ca -containing culture medium to enable synchronized re-formation of AJs (Fig. 3
C,D, Fig. S3). We found that in all tested conditions, after initial EDTA-induced loss of cell–cell contacts,
VE-cadherin AJs partially re-formed 2 h after the re-addition of regular medium (early re-formation) and
further strengthened at a late re-formation stage, 6 h after a return to regular medium (Fig. 3C). However,
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junction re-formation was slower in ΔRap1B ECs, as indicated by lower VE-cadherin fluorescence intensity
in the early re-formation stage (Fig. 3D). At the same stage, deletion of Rap1A alone led to morphologically
distinct junctions than in control or ΔRap1B ECs, as observed under basal conditions (Fig. 2A), but did not
result in quantitative differences in VE-cadherin fluorescence intensity. These findings suggest that Rap1,
and in particular the Rap1B isoform is required for establishment of VE-cadherin homophilic binding. To
further examine the role of Rap1 in the ability of VE-cadherin to form homophilic bonds, we examined
Rap1A- and Rap1B-dependent EC adhesion to substrates coated with Fc-VE-cadherin recombinant protein
(Potter et al., 2005). We found that adhesion of Rap1A KO ECs versus WT controls was significantly
decreased only at later time points (60 and 120 min), whereas adhesion of Rap1B KO ECs was significantly
decreased at all time points (Fig. 3E). Moreover, Rap1B deletion led to a greater impairment of adhesion at
all time points examined. These data show that following disruption of the EB, both Rap1 isoforms promote
re-establishment of VE-cadherin homophilic binding and junction re-formation, and deficiency of either
isoform delays AJ re-formation. A functional assessment of endothelial monolayer permeability also
indicated a trend towards initial faster recovery of the barrier in Rap1A-deficient (or siRap1A) ECs;
however, the delay was not statistically significant in Rap1B-deficient (or siRap1B) cells (Fig. S4A).
Rap1 in VEGF-induced permeability in vivo
The studies above demonstrate that both Rap1 isoforms promote de novo AJ formation and EB
establishment. Our previous studies identified Rap1 as an important regulator of VEGF–VEGFR2 signaling,
acting both downstream (Chrzanowska-Wodnicka et al., 2008) and upstream from VEGFR2 to promote
angiogenesis (Lakshmikanthan et al., 2011) and endothelial function (Lakshmikanthan et al., 2015). VEGF
is the critical factor responsible for new blood vessel formation but is also a potent permeabilizing factor,
which, under normal conditions, enables the EC junction dissolution that is required for the formation of
new vessels (Olsson et al., 2006). This raises an interesting and so far unrecognized possibility that Rap1
may be involved in the physiological response to VEGF and promote dissociation of EC junctions. To
examine the role of Rap1 isoforms in VEGF-induced vascular permeability in vivo, we subjected Rap1A-
ECKO and Rap1B-ECKO mice to the Miles assay, in which VEGF-induced extravasation of IP-injected
Evans Blue is measured in skin vessels. As expected, we found that the VEGF caused an increase in dye
leakage not only in control mice but also in Rap1A-ECKO mice (Fig. 4). Interestingly, VEGF treatment did
not lead to elevated dye leakage compared with carrier alone (BSA) in Rap1B-ECKO mice (Fig. 4). This
suggests that Rap1B is required for VEGF-induced skin microvessel permeability, whereas Rap1A is
dispensable for that process.
Rap1B promotes VEGF-induced AJ remodeling and EC permeability
The above in vivo studies suggested that Rap1B might play a role in the dynamic regulation of EC junctions
in response to VEGF stimulation. To address this hypothesis, we examined the effect of Rap1 isoform
deficiency on VEGF-induced AJ remodeling in cultured ECs by using confocal microscopy to examine the
kinetics of junctional VE-cadherin and β-catenin immunofluorescence intensity following VEGF treatment (
Fig. 5, Fig. S5). In WT ECs, the intensity of VE-cadherin and β-catenin staining was decreased 30 min after
VEGF treatment (Fig. 5B), consistent with VEGF-induced AJ disassembly (Fig. 5A). AJ
immunofluorescence intensity and cell–cell junctions were re-established after 45 min of VEGF treatment (
Fig. 5). While similar dynamics of β-catenin fluorescence intensity was observed in ΔRap1A ECs, AJ
fluorescence intensity remained unchanged in ΔRap1B ECs following VEGF treatment (Fig. 5A),
demonstrating the resistance of AJs to VEGF remodeling in Rap1B-deficient ECs.
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To examine the role of Rap1 isoforms in dynamic changes in endothelial barrier function in response to
VEGF treatment, we employed electric cell substrate impedance sensing (ECIS), an in vitro system for
quantitative measurement of cell adhesive behavior (Szulcek et al., 2014). By measuring impedance over a
range of frequencies and applying a mathematical model, this approach allows differentiation between
junctional impedance (cell–cell contact tightness) and impedance resulting from cell–substrate adhesion
(Giaever and Keese, 1991; Lo et al., 1995). EC monolayers with intact Rap1 or ECs depleted of either Rap1
isoform were subjected to VEGF and the resistivity of cell–cell contacts to the current flow, Rb, was
measured. As expected, VEGF induced a transient drop in Rb, representing transient increased permeability
in WT cells (Fig. 6A). The response to VEGF was further increased in Rap1A-deficient ECs, consistent
with decreased stability of AJs and, therefore, increased susceptibility to VEGF-induced disruption. In
contrast, the response to VEGF was consistently and significantly reduced in Rap1B-deficient cells,
representative of a resistance to VEGF-induced permeability in these cells. This result is consistent with
decreased VEGF-induced AJ remodeling (Fig. 5).
The differential effects of the two Rap1 isoforms on VEGF-induced EB dynamics suggested differential
isoform function, with Rap1B but not Rap1A required for VEGF-induced permeability. To further
investigate whether Rap1B is the only isoform mediating VEGF-induced permeability, we examined the
ability of exogenous Rap1A to rescue the defective VEGF response in Rap1B-deficient ECs. We found that
overexpression of (siRap1a-resistant) Rap1A in siRap1B ECs restored the permeability response to VEGF,
similar to that in siControl ECs (Fig. 6B). Therefore, when overexpressed, Rap1A can also promote the EC
response to VEGF.
Rap1B promotes VEGF signaling to VE-cadherin phosphorylation
VEGF-induced destabilization of cell–cell junctions at the molecular level is mediated by signaling leading
to VE-cadherin phosphorylation (Esser et al., 1998; Monaghan-Benson and Burridge, 2009). Specifically,
VEGF-induced Src-mediated VE-cadherin tyrosine phosphorylation leads to junction disassembly (Eliceiri
et al., 1999). Decreased AJ dynamics and defective EB modulation in response to VEGF treatment in
siRap1B ECs (Fig. 6) suggested that Rap1B might be involved in VEGF-induced VE-cadherin
phosphorylation. We found, as expected, that VEGF treatment led to a rapid increase in phosphotyrosine
685 in control ECs (Wallez et al., 2007) (Fig. 6C). While depletion of Rap1A did not affect that response,
depletion of Rap1B led to attenuated VEGF-induced VE-cadherin phosphorylation (Fig. 6D). To examine
whether defective signaling from VEGF to VE-cadherin contributes to decreased VE-cadherin
phosphorylation, we examined VEGF-induced Src tyrosine 416 phosphorylation corresponding to the Src
activation site. Interestingly, we found that whereas in WT and siRap1A ECs, VEGF induced rapid Src
tyrosine 416 phosphorylation, such induction was not present in siRap1B ECs, consistent with decreased Src
activation. Therefore, Rap1B promotes signaling from VEGFR2, causing phosphorylation of VE-cadherin,
which leads to dissolution of VE-cadherin junctions (Fig. 6).
Whereas a normal permeability response to VEGF is required for physiological angiogenesis, and its loss
may lead to defective development or wound healing, an aberrant response to VEGF, such as under
pathological conditions of elevated VEGF, can result in edema and tissue damage. In particular, in early
diabetes, blood–retinal barrier (BRB) breakdown leads to excessive leakage, macular edema and vision loss.
These events are largely initiated and propagated by elevated VEGF (Qaum et al., 2001). Because our above
results indicate that Rap1 is required for VEGF-induced permeability, we postulated that Rap1 deficiency
might offer protection against aberrant VEGF-induced permeability in early diabetes. To test this
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hypothesis, we examined the effect of endothelial-specific Rap1 isoform deficiency on retinal vascular
permeability in the streptozotocin-induced diabetes model (Du et al., 2002). Three weeks following
induction of diabetes, retinal vascular permeability was examined in Rap1A-ECKO, Rap1B-ECKO and
control diabetic mice. Endothelial deletion of either Rap1A or Rap1B (Fig. 7A) conferred a protective
effect. This indicates that both Rap1 isoforms are required for STZ-induced permeability and suggests that
inhibition of Rap1 function offers protection against pathological VEGF permeability.
DISCUSSION
Rap1 signaling has been implicated in increased cell adhesion and is associated with enhanced EB function
in ECs, with the roles of two closely related Rap1 isoforms, Rap1A and Rap1B, not clearly delineated in
that process. Our in vivo studies in EC-specific Rap1-knockout mice, showing the overlapping, but essential
roles of both isoforms in development but their redundancy after the formation of the EB, suggested
differential significance of Rap1 in vessel integrity establishment during development (Chrzanowska-
Wodnicka et al., 2015) and after birth (Lakshmikanthan et al., 2015). Importantly, our studies underscored
the importance of Rap1 in promoting VEGFR2 signaling (Chrzanowska-Wodnicka et al., 2008;
Lakshmikanthan et al., 2011, 2015). These findings prompted us to investigate the in vivo role of Rap1A
and Rap1B in EB maintenance, re-formation after disruption and, importantly, VEGF-mediated modulation
of EB function. The seminal findings of this paper are that both Rap1 isoforms are involved in de novo
junction formation, which is delayed in ECs lacking either isoform because of decreased VE-cadherin
binding and resulting in increased permeability and increased organ damage and mortality in vivo under
conditions of barrier disruption such as during inflammation (LPS study). Importantly, our study
demonstrates that once the EB is established, only the Rap1A isoform is required for maintenance of normal
AJ architecture and EB function specifically in the lungs, while Rap1B is redundant for these functions.
Significantly, however, in response to VEGF stimulation, Rap1B, but not Rap1A, is required for normal AJ
disassembly and EB dissociation. Therefore, our study identifies a novel role of Rap1 as a factor required
for cell–cell junction disassembly, extending the understanding of the role of Rap1 in dynamic regulation of
cell–cell adhesions and EB function.
The specific role of each Rap1 isoform in regulation of endothelial permeability has not been extensively
studied. However, in cultured ECs, Rap1A was shown to preferentially localize to cell–cell junctions, and
its depletion led to a weakening of the EB (Wittchen et al., 2011). Here, we demonstrate a functional
importance of the Rap1B, but not Rap1A isoform, in VEGF-mediated EB dissolution (Fig. 7B). This
differential role of Rap1 isoforms in regulation of the VEGF response may be explained by the differential
participation of the two isoforms in Rap1-VEGFR2 feed-forward signaling. We have previously shown that
both Rap1 isoforms act upstream of VEGFR2, promoting its activation (Lakshmikanthan et al., 2011, 2015);
however, only Rap1B is activated downstream of VEGFR2 as there is no detectable active Rap1 in Rap1B-
knockout ECs (Chrzanowska-Wodnicka et al., 2008). Therefore, it is conceivable that depletion of Rap1B
removes the feed-forward mechanism required for activation and downstream signaling from VEGFR2,
leading to the phosphorylation of VE-cadherin and AJ dissolution. Alternatively, depletion of Rap1A, which
is less abundantly expressed, may have a quantitatively lesser effect on VEGFR2 signaling; thus, when
overexpressed, Rap1A is able to rescue the deficient response to VEGF treatment in Rap1B-knockout cells.
Conversely, deletion of Rap1A, by compromising AJ stability, may increase susceptibility to VEGF-
induced dissolution (Fig. 6, Fig. 7B). Furthermore, it is likely that in addition to decreasing linear signaling
from VEGFR2 to Src, deletion of Rap1B may perturb additional VEGF-mediated AJ dissolution pathways
(Pannekoek et al., 2014). Molecular details of the complex signaling by Rap1 to VEGFR2, involving other
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receptors (Lakshmikanthan et al., 2011), remain to be fully elucidated in future studies.
Our results demonstrating that both Rap1 isoforms have a similar role in promoting de novo AJ formation
are consistent with existing in vitro models implicating Rap1 in promoting de novo junction formation
(Chrzanowska-Wodnicka, 2017). Importantly, these results may help to explain the physiological and
pathological consequences of endothelial Rap1 deficiency in vivo (Birukova et al., 2015; Chrzanowska-
Wodnicka et al., 2015; Lakshmikanthan et al., 2015). We show that deletion of either isoform, and in
particular Rap1B, delays AJ formation and EB establishment but does not prevent it. Consistently, knockout
of a single Rap1 isoform in ECs does not have a major impact on vessel integrity during vessel
development, whereas deletion of both isoforms leads to vessel leakiness, hemorrhage and death by
embryonic day 13.5 (Chrzanowska-Wodnicka et al., 2015). In contrast, after AJs are formed and the EB is
established, neither Rap1 isoform is absolutely required for the maintenance of the EB under physiological
conditions; consistently, inducible deletion of both Rap1 isoforms after birth does not grossly affect cell–
cell junction organization or vascular permeability (Lakshmikanthan et al., 2015) (Fig. 1). However, the
ability of both Rap1 isoforms to promote re-formation of EC junctions, although redundant during
development, becomes essential under pathological conditions. Specifically, both Rap1 isoforms are
involved in EC junction re-formation and promote maintenance of the EB during LPS-induced
inflammation, as endothelial knockout of each isoform leads to increased permeability, organ damage and
death (Fig. 3). Previously, Rap1A has been implicated in barrier re-formation in inflammation (Birukova et
al., 2015); our study shows that both isoforms play a key role in EB repair, and both are required for the
prevention of organ damage in sepsis. A normal permeability response to VEGF is required for angiogenesis
and any defect may interfere with normal development or wound healing; however, an aberrant response to
VEGF, such as under pathological conditions of elevated VEGF levels, leads to chronic vascular
hyperpermeability (Nagy et al., 2008) resulting in leaky vessels, edema and tissue damage associated with
multiple diseases (Weis and Cheresh, 2005). Normalization of vessels by targeting VEGF signaling is a
validated anti-angiogenesis therapy for tumor metastasis and retinopathy (Ferrara et al., 2007). Because our
results show that inhibition of Rap1B signaling reduces VEGF-induced permeability, this suggested that
inhibiting Rap1B function might offer protection against pathological VEGF permeability. Indeed, we found
that endothelial deletion of Rap1B protects against excessive vascular leakage in early diabetes, associated
with excessive VEGF signaling (Qaum et al., 2001). Interestingly, we found that deletion of Rap1A was
also protective under these conditions (Fig. 7A), supporting a synergistic role of both isoforms in promoting
signaling from VEGFR2 (Fig. 7B; Lakshmikanthan et al., 2011). These findings underscore context-
specific, dynamic regulation of both Rap1 isoforms with potential clinical implications for specific targeting
of Rap1B for the treatment of VEGF pathologies and inhibition of pathological hyper permeability.
MATERIALS AND METHODS
Reagents
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich. Human microvascular lung ECs
(HMVECs) were purchased from LONZA. RNAiMAX was from Life Technologies. Antibodies against
Rap1 (rabbit polyclonal; #4938; 1:1000), Rap1B (clone 36E1 rabbit mAb; #2326; 1:1000) and phospho-c-
Src-pY416 (rabbit polyclonal; #2101generated against a synthetic phosphopeptide corresponding to residues
surrounding Tyr419 of human Src; 1:1000) were from Cell Signaling. Antibodies against actin (clone I-19
goat polyclonal; #sc-1616; 1:1000), VE-cadherin (C-19 goat polyclonal; #sc-6458; 1:1000; F-8 mouse mAb;
#sc-9989; 1:1000) were from Santa Cruz Biotechnology. Antibody against phospho-VE-cadherin pY685
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(rabbit polyclonal; #ab119785; 1:1000) was from Abcam. Antibodies against phospho-VE-cadherin pY658
(rabbit polyclonal; #44-1144G and 44-1145G; 1:1000) were from Thermo Fisher and were used as
previously described (Adam et al., 2010; Benn et al., 2016; Wessel et al., 2014). All HRP-conjugated
secondary antibodies were from Jackson ImmunoResearch.
Genetic mouse models
All mouse procedures were performed according to approved Medical College of Wisconsin Institutional
Animal Use and Care Committee protocol 00001206. Generation of endothelial lineage-restricted Rap1-
knockout mice (Tie2-Cre ; Rap1 Rap1b , Rap1A-ECKO, and Tie2-Cre ; Rap1a Rap1 ,
Rap1B-ECKO) has been previously described (Lakshmikanthan et al., 2011). Inducible endothelial-
restricted (Rap1 ) mice were obtained by crossing mice containing floxed Rap1a or Rap1b alleles
(Rap1a Rap1b  or Rap1a Rap1b  mice) (Pan et al., 2008) with Cdh5(PAC)-CreERT2  mice and
inducing Cre activity with tamoxifen injections, as previously described (Lakshmikanthan et al., 2015;
Pitulescu et al.). Three- to twelve-month-old male and female mice were used for experiments. Mice were
anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) cocktail.
In vivo permeability assays
Basal vascular permeability to Evans Blue-labeled BSA was determined in lungs, heart, kidney and liver, as
previously described (Lakshmikanthan et al., 2015). Lipopolysaccharide (LPS)-induced permeability was
induced by intraperitoneal injection of Escherichia coli O55:B5 at 30 mg/kg, and lung vascular permeability
to Evans Blue-labeled BSA was determined 5 h post-LPS injection. Survival in the LPS-induced sepsis
model was assessed for 7 days following intraperitoneal injection of a predetermined EC  dose of LPS
(30 mg/kg). Post-LPS challenge, mice were monitored every 4–6 h and critically ill animals were
euthanized. Skin microvascular permeability to VEGF was determined using the Miles assay (Miles and
Miles, 1952). Briefly, following retro-orbital injection with 0.5% Evans Blue with 4% BSA in PBS,
anesthetized mice were injected subcutaneously with 10 µl VEGF (0.013 mg/kg body weight in 0.1% BSA
in PBS), or with 10 µl of 0.1% BSA into each side of the abdomen. After 15 min, mice were perfused with
4% paraformaldehyde in PBS and skin was dissected. Concentration of Evans Blue dye was determined
spectrophotometrically at 640 nm following dye extraction with formamide and the amount of Evans Blue
was calculated from a standard curve.
Cell culture, transfection and Ca  switch experiments
For immunofluorescence studies primary mouse lung endothelial cells (MLECs) isolated from Tie2-Cre-
negative mice (Control ECs), or Tie2 Cre-negative mice and transfected with siRap1A (ΔRap1A ECs),
Tie2-Cre ; Rap1a Rap1  or Tie2-Cre ; rap1a rap1  mice and transfected with siRap1B
(ΔRap1B ECs), were cultured in VascuLife EnGS Endothelial Medium Complete Kit, LL-0002, as
previously described (Sobczak et al., 2010). Primary human microvascular lung ECs (HMVECs; LONZA)
were used as an established model to study endothelial permeability by ECIS and VE-cadherin signaling in
response to VEGF; Rap1 deficiency was obtained by EC transfection with 50 nM Rap1a or Rap1b
siGENOME siRNA pool (Dharmacon) or with scrambled siRNA using Opti-MEM medium and RNA
iMAX reagent (Life Technologies) for 6 h and cultured for additional 36 h in EC-complete medium, until
cells reached 85% confluency.
For Ca  switch experiments, following siRNA knockdown, confluent MLECs were exposed to 4 mM
+/0 f/f +/+ +/0 +/+ f/f
iΔEC
f/f +/+ +/+ f/f +/0
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EGTA for 15 min, followed by incubation with fresh culture medium containing 1.8 mM Ca  for 6 h at
37°C, as previously described (Martinez-Palomo et al., 1980).
Western blotting
Following siRNA knockdown, 85% confluent HMVEC cultures were serum-starved for 10 h in basal EC
medium prior to VEGF-A (40 ng/ml) induction. Following treatment, as described, ECs were rapidly
washed once with ice-cold PBS and lysed with 1× RIPA buffer plus protease/phosphatase inhibitor cocktail.
Cell lysates were clarified by centrifugation at 13,800 g for 10 min at 4°C. Supernatants were flash frozen
with liquid nitrogen and stored at −80°C until further analysis. Post BCA assay, normalized total lysates
were resolved on 4–12% gradient gel and blotted using specific antibodies, as indicated. Signal intensity
was determined by densitometry of X-ray film, values obtained for phosphoproteins were normalized to
actin in the same sample and fold induction of phosphorylation over the basal phosphorylation level was
calculated.
Immunofluorescence, confocal microscopy and image analysis
MLECs were plated on fibronectin-coated coverslips (2.5 µg/ml in PBS), allowed to reach confluence,
usually 24–48 h. Following treatment, as specified, cells were fixed in 3.7% formaldehyde in PBS,
permeabilized with 0.5% Triton X-100 in PBS on ice, blocked with 1% BSA in PBS or 5% horse serum
(Atlanta Biologicals) and stained with anti-VE-cadherin (BD Pharmingen; #555289; 1:50) and monoclonal
anti β-catenin (BD Pharmingen; #610153; 1:50) antibodies, followed by appropriate secondary antibodies
(Jackson ImmunoResearch; 1:75) or Hoechst nuclear stain (1:1000 in PBS). Images were acquired using
confocal Olympus FluoView FV1000 MPE scanning microscope and analyzed with FV10-ASW 2.0
software. In all experiments, laser power was maintained at the same level for all experimental conditions
per each fluorophore and fluorescence intensity was not altered between samples during quantification.
AJ morphology was assessed by quantifying β-catenin fluorescence distribution at cell–cell contacts,
performed as in Smutny et al. (2010). Briefly, independent images with 10 randomly selected contacts were
used for quantification at every time point. A 16-μm-long line was drawn centered on, and perpendicular to,
every contact, and pixel intensities along the selected line were recorded. Data for each profile were then
imported into Prism 5 and intensities were corrected for background fluorescence by subtracting a constant
background value. A nonlinear Lorentzian curve was fitted to each profile using Prism5 (n=30). For analysis
of junction re-formation, the intensity of VE-cadherin fluorescence in AJs was quantified at 2 h (‘early re-
formation’) and 6 h (‘late re-formation’) after Ca  switch in 10 boxed areas per view, per experimental
condition (n=3).
VE-cadherin-dependent adhesion
Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF (R&D Systems; #938-VC-050;
100 µg/ml), IgG (non-specific binding control) or fibronectin (a positive control), at 5 µg/ml were coated
onto a 96-well plate format overnight at 4°C. The following day, wells were washed with PBS, blocked with
3% BSA for 2 h at RT and washed with PBS. Briefly, control or Rap1A-KO or Rap1B-KO MLECs
(passage 3) were stained with 12.5 µM calcein-AM in 0.1% BSA/PBS for 30 min at room temperature and
washed once with 0.1% BSA/PBS. Calcein-AM-labeled ECs were seeded at 30,000 cells/well density for
the indicated times and fluorescence at 515 nm measured at indicated time points (total cell fluorescence)
using a Vallac VICTOR fluorescent plate reader (PerkinElmer, Vallac, Waltham, MA). Non-adherent ECs
2+
2+
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were removed by washing with 0.1% BSA/PBS and fluorescence was measured again (adherent cell
fluorescence). VE-Cadherin homophilic adhesion was calculated as the adherent cell fluorescence to total
cell fluorescence ratio. Shown are average values from three experiments performed in triplicate.
Electrical cell impedance sensing (ECIS)
Following siRap1/control knockdown, HMVECs were seeded onto fibronectin (5 µg/ml)-coated 8W10E+
ECIS array (Applied Biophysics, MA) and allowed to reach confluence overnight. Baseline barrier was
recorded and established for at least 60 min using multiple frequency/time (MFT) setting and Rb was
modeled as previously described (Szulcek et al., 2014). VEGF-induced permeability was measured
following 100 ng/ml VEGF-A treatment. Fresh media was added after junction re-formation, ∼30 min after
VEGF-A treatment. For the gain-of-function (GOF) experiment, siRNA-transfected-HMVECs were
transduced with 6 μg/ml polybrene (hexadimethrine bromide) lentiviral particles expressing WT Rap1a
(Myc-Rap1a) at a multiplicity of infection (MOI) of 5 and ECs were cultured as described above prior to
analysis VEGF-A-induced permeability. Following the experiment, Rap1 expression was confirmed by anti-
Myc western blot analysis.
STZ diabetes model and retinal permeability assay
All animal studies were performed under a protocol approved by the Institutional Animal Care and Use
Committee and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research. Adult Rap1A-ECKO and Rap1B-ECKO mice and Cre-negative control mice were made diabetic
using multiple doses of streptozotocin (STZ) as previously described (Dominguez et al., 2016). Diabetes
was confirmed by the measurement of blood glucose in excess of 250 mg/dl on two separate days. After
3 weeks of diabetes, mice underwent assessment of retinal vascular permeability (Cai et al., 2011). Mice
received a tail vein injection of FITC-labeled albumin (0.5 mg in 50 µl vehicle). After 2 h, the mice were
euthanized and eyes enucleated. Retinas were removed, flat-mounted and kept on glass slides with
Fluoromount mounting medium (Sigma-Aldrich). Images were acquired using an Olympus FluoView 1000
scanning laser confocal microscope and at least five different view areas were selected to collect images for
each sample. All images were generated using identical settings within each experiment. Fluorescence
intensity, from a single confocal slide, was determined using ImageJ software (http://rsb.info.nih.gov).
Statistical analysis
For in vivo permeability studies, the calculated amount of extravasated Evans dye was normalized to body
weight and EB/weight measurements were analyzed. For studies involving more than two groups, one- or
two-way ANOVA was used, as appropriate, with Holm–Šidák (Figs 1 and 5) or Dunnett's (Figs 3 and 7)
adjustment for multiple comparisons. For analysis of ECIS data (Fig. 6A,B), at the time point of maximum
barrier dissolution, mean values of siRap1A or siRap1B samples were compared with mean values of
controls. For analysis of VEGF-A signaling data within each experiment, fold change in VE-cadherin
phosphorylation induction between Rap1-isoform-deficient and control values were calculated for each
condition. Mean values and s.e.m. are shown. Statistical significance of group differences was determined
using unpaired two-tailed Student's t-test.
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Rap1A is required for protection of endothelial barrier function. (A) Increased basal permeability to Evans Blue-
labeled BSA in Rap1A-ECKO (Tie2-Cre ; rap1a rap1b ) but not in Rap1B-ECKO (Tie2-Cre ; rap1a rap1b )
lungs compared with Tie2-Cre  controls in vivo. Evans Blue dye concentration in perfused lung tissue was determined
spectrophotometrically at 640 nm following dye extraction with formamide. Illustration below graph shows Rap1 isoform
content (filled circle) as an approximation of total Rap1 content in presented strains, based on immunoblots of EC lysates
(bottom). (B) Elevated lung vessel permeability in Rap1A-ECKO is endothelium autonomous; elevated vascular
permeability in Tie2-Cre ; rap1a rap1b  mice grafted with control bone marrow. Shown are actual values and mean;
error bars are s.e.m. (C) Increased basal permeability to Evans Blue-labeled BSA in Rap1A  [Cdh5(PAC)-CreERT2 ;
rap1a rap1b ] but not in Rap1B  [Cdh5(PAC)-CreERT2 ; rap1a rap1b ] lungs compared with
Cdh5(PAC)-CreERT2  controls.
Fig. 2.
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Rap1A deficiency leads to disorganized AJs. (A) Confocal images of control, ΔRap1A or ΔRap1B primary mouse lung
ECs (MLECs) grown to confluence and stained for AJ proteins, as indicated. Dispersed VE-cadherin and β-catenin staining
is visible in ΔRap1A ECs, but not in ΔRap1B ECs. The same β-catenin-stained control and ΔRap1A MLECs are also
shown in Fig. 5A. Scale bar: 20 μm. (B) Fluorescence intensity distribution across cell–cell junctions was measured in three
independent images with 10 randomly selected contacts per experimental condition. After correcting for background
fluorescence, data were nonlinear Lorentzian curve-fitted to each profile using Prism5, as previously described (Smutny et
al., 2010) and area under the curve was calculated (bottom). (C) Representative immunoblots of total Rap1 content in Rap1-
deficient ECs; actin is shown as loading control. Control and ΔRap1B MLECs were isolated from control (Tie2-Cre ;
rap1a rap1b ) or Rap1B-ECKO (Tie2 Cre ; rap1a rap1b ) P6-9 lungs. ΔRap1A ECs were obtained by knocking
down Rap1A in control cells using ‘pooled’ siRap1A.
Fig. 3.
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Both Rap1 isoforms are required for junction reformation. (A,B) Increased vascular permeability and mortality in
Rap1A-ECKO and Rap1B-ECKO mice under LPS-induced inflammatory conditions. (A) Increased vascular permeability
to Evans Blue-labeled BSA in Rap1A-ECKO and Rap1B-ECKO mice 5 h after retro-orbital injection of
lipopolysaccharides (LPS) from Escherichia coli 055:B5 (30 mg/kg). Evans Blue dye concentration was determined as in 
Fig. 1. Shown are average values, normalized, as indicated; error bars are s.e.m. (n≥12). (B) Kaplan–Meier survival curves
of mice following 30 mg/kg LPS IP injection (n=14). (C,D) Both Rap1 isoforms, and in particular Rap1B, are required for
Rap1B promotes VEGF-induced endothelial permeability and is required for dynamic regulation of the endothelial barrier
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818062/?report=printable[7/3/2019 1:42:10 PM]
de novo AJ formation. (C) Delayed VE-cadherin fluorescence recovery in AJs of Rap1-deficient ECs following AJ
disruption by Ca  switch. Confluent MLECs (‘steady state’) were treated with 4 mM EGTA for 15 min at 37°C to disrupt
endothelial cell–cell contacts (‘disassembly’). MLECs were allowed to reform AJs by further incubation in 1.8 mM Ca -
containing culture medium for 2 h (‘early re-formation’) and 6 h (‘late re-formation’). Representative confocal images are
shown. Insert in the top row shows DAPI nuclear staining. Scale bar: 20 μm. (D) The intensity of VE-cadherin fluorescence
in AJs was quantified in 10 boxed areas/view/experimental condition, as shown in the example image on the left. Graph
indicates significantly decreased fluorescence intensity in early AJ in Rap1-deficient MLECs (n=3; error bars are s.e.m.).
(E) Rap1 deletion leads to attenuated VE-cadherin homophilic binding. Time course of adhesion of calcein-AM-loaded ECs
onto Fc-VE-cadherin-coated plates protein as a measure of the ability of ECs to form AJs. Fc-IgG-coated wells serve as
negative controls (error bars are s.e.m.; n≥3).
Fig. 4.
Rap1B-ECKO mice are resistant to VEGF-induced vascular permeability. The Miles skin permeability assay was
performed in anesthetized mice retro-orbitally injected with 1 mg Evans Blue dye and then subcutaneously with 10 μl
VEGF (0.013 mg/kg body weight in 0.1% BSA in PBS) or 0.1% BSA in PBS alone (BSA) into each side of the abdomen.
2+
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After 15 min, Evans Blue dye concentration in the tissue was determined as described in Fig. 1. Shown are actual values
and means, normalized to wet skin weight; error bars are s.e.m.; P-values are indicated.
Fig. 5.
Rap1b deficiency impairs the ability of VEGF to remodel AJs. (A) Confocal images of β-catenin staining in ΔRap1A,
ΔRap1B or control confluent MLECs, serum-starved for 6 h as in Fig. 2 (control and ΔRap1A MLECs are reproduced from
Fig. 2A) and treated for indicated time with 50 ng/ml VEGF. Scale bar: 20 μm. (B) AJ fluorescence intensity distribution
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and calculation of area under the curve at corresponding time points of VEGF treatment, measured as described in Fig. 2.
After 30 min of VEGF treatment, AJs are dispersed in WT and ΔRap1A ECs, but not in ΔRap1B ECs (A, middle row), in
which fluorescence intensity is unchanged (B, middle graph). Representative images of n=3 independent experiments are
shown.
Fig. 6.
Rap1B is required for VEGF-induced EC responses and signaling: Src activation and VE-cadherin phosphorylation.
(A,B) Rap1B-deficient EC monolayers are resistant to VEGF-induced permeability. VEGF treatment (A, arrow) induces a
rapid, reversible drop in resistivity in siControl ECs and siRap1A ECs, but a reduced response in siRap1B ECs. EC barrier
function was measured using ECIS in early passage HMVECs transfected with 50 nM ‘pooled siRNAs’ for 24 h, seeded
onto 5 µg/ml fibronectin-coated 8W10E+ ECIS array, allowed to reach confluence and treated with VEGF (100 ng/ml). (B)
Rap1A overexpression rescues the loss of response to VEGF-induced barrier dissolution in siRap1B ECs. 24 h after
siRap1B knockdown, ECs were transduced with lentiviral particles expressing WT-Rap1A (Myc-tagged) at 5 MOI and
cultured for an additional 36 h prior to measuring barrier function by ECIS. Right panel shows Rap1B knockdown and
Myc/Rap1A overexpression confirmed by western blotting of lysates from EC in parallel samples. Plotted are average Rb
values obtained in a representative experiment (of >3 performed) using multiple frequency/time (MFT) setting from
triplicate wells per condition, modeled as previously described (Szulcek et al., 2014) and normalized to baseline. Values are
averages of triplicate wells per condition, error bars are s.d. At the time point of maximum barrier dissolution, mean values
of experimental samples were compared with mean values of controls. Arrow indicates VEGF treatment. (C) VEGF-
induced VE-cadherin and Src tyrosine 416 phosphorylation was examined in HMVECs transfected with control, scrambled
siRNA or Rap1A siRNA or Rap1B siRNA. Representative immunoblots of phosphorylated and total protein expression are
shown, together with actin as loading control. Note that the Src pY416 panel is from a longer exposure of the same blot to
reveal protein. (D) Quantification of fold change in VEGF-induced phosphorylation of signaling molecules in Rap1
isoform-deficient and control ECs. Rap1B, but not Rap1A deficiency leads to decreased phosphorylation of Src and VE-
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cadherin. Note that the kinetics of respective phosphorylation events implicates non-linearity in their response to VEGF
stimulation. Values are means±s.e.m. (n≥3).
Fig. 7.
Synergistic role of Rap1 isoforms in VEGFR2 signaling. Rap1 deficiency protects against increased retinal vascular
permeability in the STZ-induced diabetes model. (A) Representative retinal flat-mounts from diabetic control, Rap1A-
ECKO and Rap1B-ECKO mice injected with fluorescent dextran. Leakage is shown as hyperfluorescence extravasating
from vessels. Scale bar: 50 μm. Quantification of fluorescent leakage, obtained from a single confocal slice, demonstrates
reduced leakage in diabetic Rap1-ECKO mice compared with diabetic control mice (n≥8). (B) Proposed role of Rap1
isoforms in VEGF-mediated modulation of EC barrier function; a model built on current and published results. Rap1B,
acting downstream from VEGFR2, is the predominant isoform responsible for VEGF-induced AJ dissociation and
endothelial permeability, while both Rap1 isoforms promote full VEGFR2 activation and as such, participate in full
response to VEGF. Rap1A is the main Rap1 isoform involved in structural maintenance of AJs, and its depletion may
increase AJ susceptibility to VEGF-induced dissolution.
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